MiMedx Group/$MDXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Ticker
$MDXG
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
837
ISIN
US6024961012
Website
MiMedx Group Metrics
BasicAdvanced
$1B
24.98
$0.27
1.74
-
Price and volume
Market cap
$1B
Beta
1.74
52-week high
$9.71
52-week low
$5.47
Average daily volume
672K
Financial strength
Current ratio
4.695
Quick ratio
3.959
Long term debt to equity
8.646
Total debt to equity
9.201
Dividend payout ratio (TTM)
0.42%
Interest coverage (TTM)
15.77%
Profitability
EBITDA (TTM)
62.831
Gross margin (TTM)
81.94%
Net profit margin (TTM)
11.40%
Operating margin (TTM)
15.41%
Effective tax rate (TTM)
26.67%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
13.80%
Return on equity (TTM)
22.29%
Valuation
Price to earnings (TTM)
24.976
Price to revenue (TTM)
2.832
Price to book
4.94
Price to tangible book (TTM)
5.81
Price to free cash flow (TTM)
15.484
Free cash flow yield (TTM)
6.46%
Free cash flow per share (TTM)
43.79%
Growth
Revenue change (TTM)
5.34%
Earnings per share change (TTM)
-38.83%
3-year revenue growth (CAGR)
11.02%
10-year revenue growth (CAGR)
9.71%
3-year earnings per share growth (CAGR)
16.61%
10-year earnings per share growth (CAGR)
10.77%
What the Analysts think about MiMedx Group
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
Bulls say / Bears say
MiMedx Group reported a 3% increase in net sales for Q3 2024, reaching $84 million, driven by strong product contributions despite some sales team turnover and product declines. The company expects 2024 net sales growth to hit the high single digits, emphasizing strategic priorities and potential growth in placental tissue products. Adjusted EBITDA rose to $18 million, with a 22% margin, showcasing robust financial health amid market challenges. (tipranks.com)
MiMedx Group's CEO and Director, Joseph Capper, demonstrated strong confidence in the company's future by purchasing $1.3 million worth of stock at an average price of $6.34, increasing his holding by 61%. This significant insider buying often signals positive expectations for the company's performance. (simplywall.st)
Analysts have shown optimism towards MiMedx Group, with StockNews.com upgrading the stock from a 'buy' to a 'strong-buy' rating, and Cantor Fitzgerald maintaining an 'overweight' rating with a $13.00 target price. Such positive analyst sentiment can attract more investors and potentially drive the stock price higher. (defenseworld.net)
On December 29, 2023, MiMedx disclosed that it had received a warning letter from the U.S. Food and Drug Administration stating that the Company’s placental-derived tissue product, Axiofill, does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product. This regulatory challenge led to a 10.3% drop in the company's stock price, raising concerns about potential compliance issues and their impact on future sales. (businesswire.com)
Institutional investors, who own 45% of MiMedx Group, faced significant losses after a 7.4% drop in the company's stock price, adding to a year-long decline of 14%. Such substantial ownership by institutions means their trading decisions could further influence the stock's volatility and downward pressure. (simplywall.st)
Despite recent insider buying, there has been more insider selling of MiMedx Group stock than buying over the last year. This trend might indicate a lack of confidence among some insiders regarding the company's future prospects, potentially signaling caution to investors. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
MiMedx Group Financial Performance
Revenues and expenses
MiMedx Group Earnings Performance
Company profitability
MiMedx Group News
AllArticlesVideos
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
GlobeNewsWire·2 months ago
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
GlobeNewsWire·2 months ago
MIMEDX Announces First Quarter 2025 Operating and Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiMedx Group stock?
MiMedx Group (MDXG) has a market cap of $1B as of July 11, 2025.
What is the P/E ratio for MiMedx Group stock?
The price to earnings (P/E) ratio for MiMedx Group (MDXG) stock is 24.98 as of July 11, 2025.
Does MiMedx Group stock pay dividends?
No, MiMedx Group (MDXG) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next MiMedx Group dividend payment date?
MiMedx Group (MDXG) stock does not pay dividends to its shareholders.
What is the beta indicator for MiMedx Group?
MiMedx Group (MDXG) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.